3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Carcinoma, Renal Cell
4
Carcinoma, Hepatocellular
3
Melanoma
2
Endometrial Neoplasms
2
von Hippel-Lindau Disease
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Brain Neoplasms
1
Bone Neoplasms
1
Advanced Malignancies
1
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
1
Adenocarcinoma
1
Interventions
lutetium Lu 177 dotatate
5
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
pembrolizumab
2
olaparib
2
fludarabine
2
cabozantinib
2
X-Rays
2
Phantoms, Imaging
2
Cyclophosphamide
2
tivozanib
1
repotrectinib
1
pazopanib
1
fludarabine phosphate
1
entrectinib
1
belinostat
1
atezolizumab
1
aldesleukin
1
Yttrium-90
1
Tomography, X-Ray Computed
1
Tomography, Emission-Computed, Single-Photon
1
Temozolomide
1
Single Photon Emission Computed Tomography Computed Tomography
1
Salts
1
Positron Emission Tomography Computed Tomography
1
PT-100 dipeptide
1
Octreotide
1
Nivolumab
1
Introns
1
Interferon alpha-2
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
lenvatinib
×
30 days
×
Clear all
No trials found.